Arthemeter-lumefantrine — Competitive Intelligence Brief

Arthemeter-lumefantrine (Arthemeter-lumefantrine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

phase 3 Antimalarial combination Plasmodium falciparum heme detoxification pathway; mitochondrial electron transport Infectious Disease Small molecule

Target snapshot

Arthemeter-lumefantrine (Arthemeter-lumefantrine) — Research Institute for Tropical Medicine, Philippines. Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arthemeter-lumefantrine TARGET	Arthemeter-lumefantrine	Research Institute for Tropical Medicine, Philippines	phase 3	Antimalarial combination	Plasmodium falciparum heme detoxification pathway; mitochondrial electron transport
Amodiaquine plus sulphadoxine-pyrimethamine combination	Amodiaquine plus sulphadoxine-pyrimethamine combination	Centre for Global Health Research, Ghana	marketed	Antimalarial combination	Plasmodium dihydrofolate reductase, dihydropteroate synthase, and hemozoin formation
Artesunate/mefloquine (AS/MQ)	Artesunate/mefloquine (AS/MQ)	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium falciparum (parasite); artesunate targets heme-dependent pathways; mefloquine targets parasite membrane and heme detoxification
Artesunate and Pyronaridine	Artesunate and Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Malaria parasite (Plasmodium species) — multiple targets including heme polymerization and oxidative stress pathways
Artesunate + Mefloquine	Artesunate + Mefloquine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced reactive oxygen species; mefloquine-heme polymerase inhibition)
Tafenoquine plus DHA-Piperaquine	Tafenoquine plus DHA-Piperaquine	Menzies School of Health Research	marketed	Antimalarial combination	Plasmodium hypnozoites (tafenoquine); Plasmodium blood-stage parasites (DHA-piperaquine)
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class